Aromatase inhibitors, either alone or in combination with growth hormone, can boost final height in mid-pubertal boys with ...

Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

Nikki Odum was on vacation with her family when she noticed something unusual — a strange shape under her armpit near her left breast. At 36 years old, this discovery was both unexpected and alarming.

Researchers have found new compounds that could be used to treat a common breast cancer that can be resistant to hormone ...

Hormone receptor (HR)-positive HER2-negative advanced breast cancer is incurable and the aim of treatment is to delay it getting worse and extend how long people live. If the cancer has alterations in ...

AstraZeneca’s (AZ) AKT inhibitor Truqap (capivasertib) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a combination treatment for advanced breast ...

AKT inhibitor Truqap (capivasertib) has been cleared by NICE for use in combination with standard therapy fulvestrant for ...

The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective ...

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment ...